

This was a randomized study of the effect of ivabradine versus placebo on peak oxygen uptake in chronic heart transplant recipients. Unfortunately the study got severely impacted by COVID-19 (which of course made it unsafe for immunosuppressed patients to go to the hospital for study visits during the pandemic), and the study was terminated prematurely after inclusion of 10 patients of whom only a few completed the study. For logistic reasons including funding and staffing, it was not possible to restart the study after resolution of the pandemic.

As such there are and will be no scientifically meaningful partial or preliminary results to communicate from the trial.

Finn Gustafsson, MD, PhD, sponsor.